biostudies-literatureUnknown77Bar Y<h4>Background</h4>Early invasive ductal carcinoma (IDC) breast cancer often presents with a coexisting ductal carcinoma in situ (DCIS) component, while about 5 % of cases present with an extensive (>25 %) intraductal component (EIC). The impact of EIC on the genomic risk of recurrence is unclear.<h4>Methods</h4>Patients with early hormone receptor-positive HER2neu-negative (HR + HER2-) IDC breast cancer and a known OncotypeDX Breast Recurrence Score® (RS) who underwent breast surgery at our institute were included. Using a rule-based text-analysis algorithm, we analyzed pathological reports and categorized patients into three groups: EIC, non-extensive DCIS (DCIS-L), and pure-IDC (NO-DCIS). Genomic risk was determined using OncotypeDX RS.<h4>Results</h4>A total of 33 (4.6 %) EIC cases, 37Breast (Edinburgh, Scotland)103777https://www.ebi.ac.uk/biostudies/studies/S-EPMC11325798biostudies-literatureThe impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer.PMC11325798Bar KLerner SShahoha MBar YShachar SSDershowitz NFeldman DDror JBSonnenblick AWeiss-Meilik AWolf IfalseThe impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer.<h4>Background</h4>Early invasive ductal carcinoma (IDC) breast cancer often presents with a coexisting ductal carcinoma in situ (DCIS) component, while about 5 % of cases present with an extensive (>25 %) intraductal component (EIC). The impact of EIC on the genomic risk of recurrence is unclear.<h4>Methods</h4>Patients with early hormone receptor-positive HER2neu-negative (HR + HER2-) IDC breast cancer and a known OncotypeDX Breast Recurrence Score® (RS) who underwent breast surgery at our institute were included. Using a rule-based text-analysis algorithm, we analyzed pathological reports and categorized patients into three groups: EIC, non-extensive DCIS (DCIS-L), and pure-IDC (NO-DCIS). Genomic risk was determined using OncotypeDX RS.<h4>Results</h4>A total of 33 (4.6 %) EIC cases, 372024-01-01T00:00:00Z2024 Jul2025-04-21T22:07:14.115Z2025-04-05T18:35:00.075ZS-EPMC113257983903842510.1016/j.breast.2024.103777